Private Client Services LLC Purchases Shares of 5,864 Bristol-Myers Squibb (NYSE:BMY)

Private Client Services LLC purchased a new stake in shares of Bristol-Myers Squibb (NYSE:BMY) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 5,864 shares of the biopharmaceutical company’s stock, valued at approximately $301,000.

Several other institutional investors have also added to or reduced their stakes in BMY. Dakota Wealth Management purchased a new position in shares of Bristol-Myers Squibb in the 1st quarter worth approximately $332,000. Covestor Ltd boosted its holdings in shares of Bristol-Myers Squibb by 111.5% in the 1st quarter. Covestor Ltd now owns 2,052 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 1,082 shares during the period. NewEdge Advisors LLC boosted its holdings in shares of Bristol-Myers Squibb by 53.2% in the 1st quarter. NewEdge Advisors LLC now owns 165,336 shares of the biopharmaceutical company’s stock worth $12,075,000 after purchasing an additional 57,444 shares during the period. Ergoteles LLC bought a new stake in shares of Bristol-Myers Squibb during the 1st quarter worth approximately $1,997,000. Finally, Mackenzie Financial Corp lifted its stake in shares of Bristol-Myers Squibb by 25.1% during the 1st quarter. Mackenzie Financial Corp now owns 338,563 shares of the biopharmaceutical company’s stock worth $24,725,000 after acquiring an additional 68,018 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Up 0.1 %

Shares of BMY stock opened at $48.54 on Tuesday. Bristol-Myers Squibb has a 1-year low of $47.58 and a 1-year high of $70.93. The stock’s fifty day moving average price is $51.29 and its 200 day moving average price is $51.69. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.43 and a quick ratio of 1.31. The company has a market cap of $98.38 billion, a price-to-earnings ratio of 12.57, a price-to-earnings-growth ratio of 1.78 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.55 by $0.15. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The firm had revenue of $11.48 billion for the quarter, compared to the consensus estimate of $11.19 billion. During the same period in the previous year, the business earned $1.82 EPS. The firm’s revenue for the quarter was up .6% on a year-over-year basis. On average, research analysts expect that Bristol-Myers Squibb will post 5.41 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be paid a dividend of $0.60 per share. The ex-dividend date is Thursday, April 4th. This represents a $2.40 annualized dividend and a yield of 4.94%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 62.18%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Redburn Atlantic lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $77.00 to $54.00 in a research note on Tuesday, February 6th. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Finally, Wells Fargo & Company decreased their target price on Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 6th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average price target of $61.12.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.